Novo Nordisk stock news
On April 30, 2026, the U.S. Food and Drug Administration (FDA) proposed excluding semaglutide and liraglutide from the 503B bulks list, a regulatory shift that would prevent outsourcing facilities from compounding these medications. This action is expected to significantly mitigate competition from unapproved, compounded versions of Wegovy and Ozempic, as the agency found "no clinical need" for compounding from bulk substances. Following the announcement, Novo Nordisk (NVO) shares experienced an intraday gain of approximately 4.8%, marking a notable recovery for the stock.